Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.G. Yeni, S.M. Hammer, C. Carpenter, M.S. Hirsch, M.S. Sagg, M. Schechtern, et al.
A. Antiretroviral therapy for adult HIV infection in 2004.
JAMA, 288 (2004), pp. 222-235
[2.]
S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, J.S. Currier, et al.
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
N Engl J Med, 337 (1997), pp. 725-733
[3.]
F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
N Engl J Med, 338 (1998), pp. 853-860
[4.]
D. Finzi, J. Blankson, J.D. Siliciano, J.B. Margolick, K. Chadwick, T. Pierson, et al.
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nat Med, 5 (1999), pp. 512-517
[5.]
R.J. Pomerantz.
Residual HIV-1 disease in the era of highly active antiretroviral therapy.
N Engl J Med, 340 (1999), pp. 1672-1674
[6.]
T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. Di Giuseppe, H. Taylor, et al.
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Nature, 387 (1997), pp. 183-188
[7.]
C. Vidal, M. Arnedo, F. Garcia, G. Mestre, M. Plana, A. Cruceta, et al.
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therpay with stavudine, didanosine and nevirapine.
Antivir Ther, 7 (2002), pp. 27-31
[8.]
D. Podzamczer, E. Ferrer, E. Consiglio, J.M. Gatell, P. Pérez, J.L. Pérez, et al.
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Antivir Ther, 7 (2002), pp. 81-90
[9.]
J.R. Arribas, F. Pulido, R. Delgado, A. Lorenzo, P. Miralles, A. Arranz, et al.
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
J Acquir Immune Defic Syndr, 40 (2005), pp. 280-287
[10.]
J.C. Gathe, P. Ive, R. Wood, D. Shürmann, N.C. Bellos, E. De Jesús, et al.
SOLO: 48 weeks efficacy and safety comparison of once daily fosamprenavir/ritonavir versus twice daily nelfinavir in naïve HIV-1 infected patients.
AIDS, 18 (2004), pp. 1529-1537
[11.]
C. Dalban, G. Peytavin, C. Lamotte, A.G. Marcelin, R. Agher, C. Delaugerre, et al.
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrob Agents Chemother, 48 (2004), pp. 4687-4692
[12.]
R. Colonno, R. Rose, C. McLaren, A. Thiry, N. Parkin, J. Friborg.
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
J Infect Dis, 189 (2004), pp. 1802-1810
[13.]
J. Arribas, A. Pozniak, J. Gallant, et al.
Three-year safety and efficacy of emtricitabine (FT)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) in antiretroviral treatment-naive patients [Abstract WEPEB029].
4th IAS Conference HIV Pathogenesis, Treatment and Prevention,
[14.]
J.V.R. Madruga, I. Cassetti, E. Koenig, A. Etzel, Y. Zhou, A.K. Cheng, For the 903E Study Team, et al.
Six Year Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naïve Patients.
4th IAS Conference HIV Pathogenesis, Treatment and Prevention,
[15.]
S. Staszewski, J. Morales Ramirez, K.T. Tashima, A. Rachilis, D. Skiest, J. Stanford, et al.
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
N Engl J Med, 341 (1999), pp. 1865-1873
[16.]
F. Van Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, For the 2 NN Study Team.
Comparison of first line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomized open label trial, the 2NN study.
Lancet, 363 (2004), pp. 1253-1263
[17.]
E. Martinez, J.A. Arnaiz, D. Podzamzcer, D. Dalmau, E. Ribera, P. Domingo, for the Nevirapine, Efavirenz and Abacavir (NEFA) Study Team.
Substitution of nevirapine, efavirenz or abacavir for portease inhibidors in patients with human immunodeficiency virus infection.
N Engl J Med, 349 (2003), pp. 1036-1046
[18.]
R.M. Gulick, A. Meibohm, D. Havlir, J.J. Eron, A. Mosley, J.A. Choolakewitz, et al.
Six year follow up of HIV-1 infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine and lamivudine.
AIDS, 17 (2003), pp. 2345-2349
[19.]
S. Walmsley, B. Bernstein, M. King, S. Arribas, G. Beall, P. Ruane, For the M98-863 Study Team.
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
N Engl J Med, 346 (2002), pp. 2039-2046
[20.]
M. Markowitz, J.O. Morales-Ramirez, B.Y. Nguyen.
Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1 Infected Individuals. Study 004.
J Acquir Immune Defic Syndr, 43 (2006), pp. 509-515
[21.]
Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, for the Protocol 004 part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection. Results of a 48-week controlled study. JAIDS. 2007 [en prensa].
[22.]
B. Grinsztejn, B.Y. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, D. Vittecoq, For the protocol 005 Team.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial (Study 005).
Lancet, 369 (2007), pp. 1261-1269
[23.]
Steigbigel RT, Cooper D, et al, for the BENCHMRK Study Team. Efficacy and safety of the HIV integrase inhibitor raltegravir (MK-0518) combined with optimized background therapy in treatment experienced patients with unsuppressed multi-drug resistant HIV-1 infection. Primary results of the BENCHMRK 1 and 2 phase III trials. N Engl J Med. 2008 [en prensa].
[24.]
Cooper D, Steigbigel RT, Gatell JM, et al, for the BENCHMRK Team. Efficacy of the HIV-integrase-inhibitor raltegravir (MK-0518) combined with optimized background therapy in treatment experienced patients with unsuppressed multi-drug resistant HIV-1 infection. Subgroup and resistance analyses from the BENCHMRK 1 and 2 phase III trials. N Engl J Med. 2008 [en prensa].
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
